uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV Investor and Analyst Breakfast Transcript

Dec 09, 2019 / 12:00PM GMT
Release Date Price: $63.31
Maria E. Cantor
uniQure N.V. - SVP of IR & Communication

Good morning, and thank you for joining us as we review the 12-month follow-up data from the Phase IIb study of EtranaDez, AMT-061 and the 4-year follow-up data on AMT-060, it being studied in patients with hemophilia B that were presented this weekend at the ASH Annual Meeting here in Orlando. I'm Maria Cantor, Senior Vice President of Investor Relations and Corporate Communications at uniQure. Joining me for this event and webcast are Matt Kapusta, our Chief Executive Officer; Dr. Robert Gut, our Chief Medical Officer; and Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the University of Michigan and a Principal Investigator in the HOPE-B pivotal trial of EtranaDez.

The data presentations from uniQure that were presented this weekend at ASH are available on the investor page of our corporate website under Investor Downloads. And today's webcast presentation will be available on our website at the conclusion of this event.

Please

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot